STAR
Strides Pharma Science share price & financials
- Price
- ₹1,074.9
- Market cap
- ₹10.9k Cr
- Sector
- Healthcare
- Calls analysed
- 6
Strides Pharma Science Limited Q1 FY27
What went well
- Topline grew 13% year-on-year, supported by broad-based contributions across businesses.
- Ex-US markets demonstrated strong momentum, delivering 17% year-on-year growth to ₹587.5 crores.
- Gross margin expanded 60 basis points year-on-year to 60.9%, driving 14% growth in absolute gross margin to ₹770.2 crores.
What to watch
- US business revenue of ₹628.2 million ($68 million) reflected stable performance despite increased competition.
- Ex-US revenue of $63 million was impacted by supply chain disruptions and shipment delays, a sequential dip from $70 million in Q4 FY26.
What Strides Pharma Science Limited does
Strides Pharma Science is a Bengaluru-headquartered global pharmaceutical company that develops, manufactures and markets generic finished-dosage medicines. It earns revenue through a direct commercial business in the US and Other Regulated Markets (UK, Nordics, Australia), an emerging-markets Growth business spanning Africa and expanding into LATAM, MENA and APAC, and a separate institutional business that supplies donor-funded and tender-based Access Markets. The company runs manufacturing operations in India (Bengaluru, Puducherry and the Chennai/Alathur region), Italy (Milan) and Kenya (Nairobi), with a commercial presence in the US (New York). Its pipeline is expanding into complex generics such as nasal sprays, transdermal patches and films alongside its established portfolio of commercialized generic products.
Segments
- US Market
- Other Regulated Markets (ORM)
- Growth Markets
- Access Markets (Institutional)
- Manufacturing divisions in India
- 4 (Bengaluru – Jigani & Chandapura, Puducherry, Alathur)
- Global manufacturing/commercial footprint
- India, Italy (Milan), Kenya (Nairobi) and the United States (New York)
- Commercialized products in the US market
- 70
- US products with top-3 market-share ranking
- 37 products, contributing ~75% of US revenue
- New product activity in FY26 (US)
- 6 new products launched; 9 discontinued for not meeting margin threshold
- Complex-generics pipeline platforms
- Nasal sprays, transdermal patches and films
Guidance record · Q1 FY27
what the last two calls moved 12 tracked 2 delivered 0 missed 10 open- Gross Margin delivered said Q1 FY26 Promised: 58% to 60% is a good range for us to remain in Q1 FY27: Achieved 60.9%, exceeding the guided 58-60% range. Commitment to the range reiterated.
- US Revenue Target on track said Q4 FY25 Promised: $400 million objective... next 2 years Q1 FY27: Reiterated aspiration of '$375 million North America business by FY28'. Q1 US revenue at $68M.
All 12 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 12.9%, net profit up 55.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,167 | 1,154 | 1,190 | 1,120 | 1,221 +5% | 1,195 +4% | 1,323 +11% | 1,265 +13% |
| EBITDA | 184 | 210 | 218 | 218 | 231 +26% | 236 +12% | 240 +10% | 228 +5% |
| Net profit | 72 | 90 | 86 | 106 | 132 +83% | 208 +131% | 129 +50% | 165 +56% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +35.6% 1Y
1Y: ₹872.45 on 10 Sept 2025 → ₹1,183.4. High ₹1,217 (10 Sept 2026), low ₹793.55 (27 Jan 2026).
How the price took the results
close before → close after
- Q1 FY27
- −4.5%
- 31 Jul
- Q4 FY26
- −0.2%
- 18 May
- Q3 FY26
- +8.3%
- 30 Jan
- Q2 FY26
- +9.7%
- 31 Oct
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 9.6% a year over 3 years, FY23 to FY26. Operating margin widened to 19.0%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹3.7k Cr | ₹4.0k Cr | ₹4.6k Cr | ₹4.9k Cr |
| Operating profit | ₹145 Cr | ₹543 Cr | ₹800 Cr | ₹925 Cr |
| Operating margin | 3.9% | 13.6% | 17.5% | 19.0% |
| Interest | ₹262 Cr | ₹296 Cr | ₹249 Cr | ₹178 Cr |
| Depreciation | ₹243 Cr | ₹217 Cr | ₹192 Cr | ₹203 Cr |
| Net profit | ₹-212 Cr | ₹-94 Cr | ₹3.6k Cr | ₹575 Cr |
| Net margin | -5.7% | -2.4% | 78.8% | 11.8% |
| Cash from operations | ₹44 Cr | ₹701 Cr | ₹684 Cr | ₹703 Cr |
| Free cash flow | ₹-43 Cr | ₹672 Cr | ₹505 Cr | ₹291 Cr |
| ROCE | 0.0% | 7.0% | 15.0% | 18.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹90 Cr | ₹90 Cr | ₹90 Cr | ₹92 Cr | ₹92 Cr | ₹92 Cr |
| Reserves | ₹2.7k Cr | ₹2.3k Cr | ₹2.1k Cr | ₹2.0k Cr | ₹2.7k Cr | ₹3.0k Cr |
| Borrowings | ₹2.3k Cr | ₹3.0k Cr | ₹3.0k Cr | ₹2.5k Cr | ₹1.8k Cr | ₹1.8k Cr |
| Other liabilities | ₹1.8k Cr | ₹1.6k Cr | ₹1.4k Cr | ₹1.2k Cr | ₹1.9k Cr | ₹1.9k Cr |
| Total liabilities | ₹7.0k Cr | ₹6.9k Cr | ₹6.6k Cr | ₹5.8k Cr | ₹6.5k Cr | ₹6.8k Cr |
| Fixed assets | ₹2.2k Cr | ₹2.3k Cr | ₹2.3k Cr | ₹1.9k Cr | ₹2.1k Cr | ₹2.1k Cr |
| Capital work in progress | ₹447 Cr | ₹291 Cr | ₹151 Cr | ₹162 Cr | ₹164 Cr | ₹447 Cr |
| Investments | ₹697 Cr | ₹540 Cr | ₹490 Cr | ₹303 Cr | ₹440 Cr | ₹291 Cr |
| Other assets | ₹3.6k Cr | ₹3.8k Cr | ₹3.6k Cr | ₹3.5k Cr | ₹3.8k Cr | ₹4.0k Cr |
| Total assets | ₹7.0k Cr | ₹6.9k Cr | ₹6.6k Cr | ₹5.8k Cr | ₹6.5k Cr | ₹6.8k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, DIIs added +2.12 pp while the public trimmed −2.10 pp. The shareholder count grew 2% to 94,850.
- Promoters
- 27.9%
- FIIs
- 28.4%
- DIIs
- 15.4%
- Government
- 0.0%
- Public
- 28.3%
Since Jun 2025
- DIIs +2.12 pp
- Public −2.10 pp
- Promoters −0.39 pp
How it drifted, 12 quarters
Over this window FIIs went from 17.3% to 28.4% — +11.2 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 27.8%, FIIs 17.3%, DIIs 19.5%, Government 0.4%, Public 35.1%.Dec '23: Promoters 27.4%, FIIs 19.4%, DIIs 19.0%, Government 0.4%, Public 33.8%.Mar '24: Promoters 25.9%, FIIs 24.6%, DIIs 17.7%, Government 0.4%, Public 31.5%.Jun '24: Promoters 25.9%, FIIs 26.7%, DIIs 18.2%, Government 0.4%, Public 28.9%.Sep '24: Promoters 25.8%, FIIs 30.1%, DIIs 18.2%, Government 0.0%, Public 25.8%.Dec '24: Promoters 26.8%, FIIs 28.5%, DIIs 16.9%, Government 0.0%, Public 27.8%.Mar '25: Promoters 28.3%, FIIs 28.3%, DIIs 13.7%, Government 0.0%, Public 29.6%.Jun '25: Promoters 28.3%, FIIs 28.0%, DIIs 13.3%, Government 0.0%, Public 30.4%.Sep '25: Promoters 27.9%, FIIs 28.5%, DIIs 13.0%, Government 0.0%, Public 30.6%.Dec '25: Promoters 27.9%, FIIs 29.5%, DIIs 13.0%, Government 0.0%, Public 29.6%.Mar '26: Promoters 27.9%, FIIs 28.7%, DIIs 14.4%, Government 0.0%, Public 29.0%.Jun '26: Promoters 27.9%, FIIs 28.4%, DIIs 15.4%, Government 0.0%, Public 28.3%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Quant Mutual Fund - Quant Healthcare Fund Mutual fund newly disclosed 5.59% held
- SBI Life Insurance Co. Ltd Insurer +0.51 pp 4.76% held
The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Strides Pharma Science Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Pronomz Ventures Llp | 19.62% | unchanged |
| Quant Mutual Fund - Quant Healthcare Fund Mutual fund | 5.59% | newly disclosed |
| Route One Offshore Master Fund, L.P. FPI fund | 5.05% | unchanged |
| SBI Life Insurance Co. Ltd Insurer | 4.76% | +0.51 pp |
| Karuna Business Solutions Llp | 3.50% | unchanged |
| Route One Fund I, L.P. FPI fund | 2.17% | unchanged |
| Arun Kumar Pillai | 2.02% | unchanged |
| Bandhan Nifty Total Market Index Fund Mutual fund | 1.63% | unchanged |
| Satpal Khattar | 1.60% | unchanged |
| K R Ravishankar | 1.36% | unchanged |
| Abu Dhabi Investment Authority - Monsoon Sovereign | 1.33% | unchanged |
| Authum Investment And Infrastructure Limited NBFC / DFI | 1.28% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
All earnings calls (6)
Read the Q1 FY27 call →Learn to analyse Strides Pharma Science Limited
Guides on how to read this kind of business and the numbers that matter.